ORTX Orchard Therapeutics plc

Price (delayed)

$1.27

Market cap

$159.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.23

Enterprise value

$141.64M

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. The company's ...

Highlights
The company's gross margin rose by 22% QoQ and by 21% YoY
ORTX's EPS is up by 25% year-on-year but it is down by 8% since the previous quarter
The equity has increased by 17% year-on-year but it has declined by 9% since the previous quarter
The revenue has plunged by 63% YoY and by 40% from the previous quarter
The gross profit has shrunk by 55% YoY and by 27% QoQ

Key stats

What are the main financial stats of ORTX
Market
Shares outstanding
125.5M
Market cap
$159.38M
Enterprise value
$141.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
135.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
118.82
Earnings
Revenue
$1.19M
EBIT
-$138.68M
EBITDA
-$136.58M
Free cash flow
-$105.39M
Per share
EPS
-$1.23
Free cash flow per share
-$0.83
Book value per share
$1.92
Revenue per share
$0.01
TBVPS
$2.75
Balance sheet
Total assets
$355.66M
Total liabilities
$114.36M
Debt
$60.84M
Equity
$241.3M
Working capital
$247.22M
Liquidity
Debt to equity
0.25
Current ratio
6.59
Quick ratio
5.86
Net debt/EBITDA
0.13
Margins
EBITDA margin
-11,458.1%
Gross margin
81.1%
Net margin
-11,900.7%
Operating margin
-11,987.5%
Efficiency
Return on assets
-40.8%
Return on equity
-57.9%
Return on invested capital
-50.1%
Return on capital employed
-44.5%
Return on sales
-11,634.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORTX stock price

How has the Orchard Therapeutics stock price performed over time
Intraday
-5.93%
1 week
-13.01%
1 month
-35.86%
1 year
-73.81%
YTD
-70.6%
QTD
-44.78%

Financial performance

How have Orchard Therapeutics's revenue and profit performed over time
Revenue
$1.19M
Gross profit
$967,000
Operating income
-$142.89M
Net income
-$141.86M
Gross margin
81.1%
Net margin
-11,900.7%
The net margin has dropped by 132% year-on-year and by 89% since the previous quarter
Orchard Therapeutics's operating margin has shrunk by 129% YoY and by 76% QoQ
The revenue has plunged by 63% YoY and by 40% from the previous quarter
The gross profit has shrunk by 55% YoY and by 27% QoQ

Growth

What is Orchard Therapeutics's growth rate over time

Valuation

What is Orchard Therapeutics stock price valuation
P/E
N/A
P/B
0.66
P/S
135.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
118.82
ORTX's EPS is up by 25% year-on-year but it is down by 8% since the previous quarter
The price to book (P/B) is 70% less than the last 4 quarters average of 2.2
The equity has increased by 17% year-on-year but it has declined by 9% since the previous quarter
The revenue has plunged by 63% YoY and by 40% from the previous quarter
The P/S is 46% less than the last 4 quarters average of 252.3

Efficiency

How efficient is Orchard Therapeutics business performance
ORTX's return on sales has dropped by 129% year-on-year and by 90% since the previous quarter
The return on assets is up by 15% year-on-year but it has declined by 8% since the previous quarter
The ROIC has contracted by 12% from the previous quarter but it has grown by 4% YoY
Orchard Therapeutics's ROE has increased by 12% YoY but it has decreased by 9% from the previous quarter

Dividends

What is ORTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORTX.

Financial health

How did Orchard Therapeutics financials performed over time
Orchard Therapeutics's total liabilities has increased by 25% YoY and by 14% QoQ
The total assets has grown by 19% YoY but it has contracted by 2.5% from the previous quarter
The debt is 75% smaller than the equity
The equity has increased by 17% year-on-year but it has declined by 9% since the previous quarter
ORTX's debt to equity is down by 11% YoY but it is up by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.